Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD (ACTIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04759105
Recruitment Status : Recruiting
First Posted : February 18, 2021
Last Update Posted : February 18, 2021
Sponsor:
Collaborators:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Center for Outcomes Research and Clinical Epidemiology, Italy
Information provided by (Responsible Party):
Gianluca Vadalà, Campus Bio-Medico University

Brief Summary:

ACTIVE is a phase II B efficacy monocenter, prospective, randomized, controlled double blinded trial, in which intra-discal autologous adult BM-MSC therapy will be compared with sham treated controls.

This trial will evaluate the efficacy of intradiscal injection of autologous BM-MSCs in workers affected by chronic low back pain (LBP) unresponsive to conventional therapy.

The efficacy will be evaluated 12 months after the treatment in terms of pain relief (VAS, Visual Analog Scale), functionality (ODI, Oswestry Disability Index), quality of life (SF36, Short Form - 36) and work ability index (WAI).


Condition or disease Intervention/treatment Phase
Intervertebral Disc Degeneration Chronic Low-back Pain Drug: Autologous BM-MSC Other: Sham Procedure Phase 2

Detailed Description:
Low back pain (LBP) is the main cause of disability in the world, affecting all occupational sectors with different incidence rates. It is estimated that 60 percent of all workers suffer from LBP during their careers, 10 percent of which become chronic (The Lancet. September 2017). Intervertebral disc degeneration (IDD) is widely recognized as a major contributor to LBP, responsible for at least 40 percent of cases. A key characteristic of IDD is loss of matrix integrity and biomechanical functional failure. Today, no therapy can restore intervertebral disc (IVD) function or provide long-term relief from symptomatic IDD. Current therapies are aimed at pain reduction. When these treatments fail, several types of surgery are performed but they are often related to side effects, disturbance of motion and other biomechanical consequences. New strategies concentrate on treating IDD at an early stage. Encouraging results from phase 1 and 2 clinical trials suggest that cell-based regenerative therapies may provide the world first effective therapy for LBP. LBP patients treated with bone marrow mesenchymal stromal/stem cells (BM-MSC) showed rapid and progressive improvement of functional indexes of 65 percent to 78 percent over 1 year after intradiscal administration without side effect. ACTIVE is an ambitious randomized clinical trial aimed at developing a treatment for IDD based on intradiscal injection of autologous BM-MSC to improve the quality of life of workers and the disability of patients with LBP. ACTIVE main aim is to generate efficacy and safety profiles of single injections of 15 million cells/mL of autologous BM-MSC for each disc affected by IDD (up to 4 discs) versus sham procedure. The regenerative potential of BM-MSC treatment will be assessed by Magnetic Resonance Imaging (MRI) technologies on quarterly basis up to 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients will be randomized in 2 arms of 26 patients and followed up for 12 months.
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description: The randomization result will be a treatment code. The treatment code of the patient will be transmitted to local pharmacy. Blinding or masking will be carried out at all stages of packaging and conditioning for shipping following the treatment allocation. Injections used for all groups will be clear and indistinguishable from each other.
Primary Purpose: Treatment
Official Title: Autologous Mesenchymal Stem/Stromal Cells for the Treatment of Workers Affected by Chronic Low Back Pain Due to Multilevel InterVErtebral Disc Degeneration: a Phase IIB Randomized Clinical Trial
Actual Study Start Date : November 17, 2020
Estimated Primary Completion Date : July 31, 2021
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arm Intervention/treatment
Experimental: Autologous BM-MSC injection

Two interventions:

  • Bone marrow harvesting from the posterior superior iliac crest region
  • Single injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control
Drug: Autologous BM-MSC
intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
Other Name: Treated

Sham Comparator: Sham Procedure

Two sham procedures:

  • Simulated bone marrow harvesting without insertion into the posterior iliac crest region
  • Simulated injection under only local anaesthesia without disc injection, without placebo injection.
Other: Sham Procedure
anaesthesia, no disc injection, no placebo injection
Other Name: Sham




Primary Outcome Measures :
  1. Pain clinical relief [ Time Frame: Baseline to month 12 ]
    Pain clinical reduction of at least 40 percent on Visual Analogic Scale (VAS) between baseline and month 12. VAS pain scale ranges from 0 to 100, where 0 represents no pain and 100 represents the worst pain imaginable.

  2. Functional disability index improvement [ Time Frame: Baseline to month 12 ]
    Functional disability reduction of 40 percent on Oswestry Disability Index (ODI, also known as the Oswestry Low Back Pain Disability Questionnaire) at month 12 compared with baseline. ODI scale ranges from 0 to 50 and allows evaluation of disability (0 - 20 percent: minimal disability; 20 - 40 percent: moderate disability; 40 - 60 percent: severe disability; 60 - 80 percent: crippled; 80 - 100 percent: bed-bound or exaggerating their symptoms).

  3. Work ability improvement [ Time Frame: Baseline to month 12 ]
    Improvement of 10 percent on Work Ability Index (WAI) at month 12 compared to baseline. The WAI is composed of 7 items and is a validated instrument that assesses the individual work ability of an employee. The total WAI score ranges from 7 to 49 and is calculated by summing up the scores of the 7 items.


Secondary Outcome Measures :
  1. Measure pain relief of the patient [ Time Frame: Baseline, 1, 3 and 6 months ]
    Assessed by Visual Analogic Scale (VAS). VAS pain scale ranges from 0 to 100: where 0 represents no pain and 100 represents the worst pain imaginable.

  2. Measure functional disability index of the patient [ Time Frame: Baseline, 1, 3 and 6 months ]
    Assessed by ODI (Oswestry Low Back Pain Disability Questionnaire) scale which ranges from 0 to 50 (0 - 20 percent: minimal disability; 20 - 40 percent: moderate disability; 40 - 60 percent: severe disability; 60 - 80 percent: crippled; 80 - 100 percent: bed-bound or exaggerating their symptoms).

  3. Evaluate disability and quality of life evolution of the patient [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    Assessed by Short Form-36 Health Survey (SF-36) scores which consist of eight 0-100 scaled scores (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning and mental health) where a lower score corresponds to more disability and a higher score corresponds to less disability.

  4. Disability and quality of life evolution [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    Assessed by the patient and the physician on: pain intensity in the lumbar spine (1 = none, 2 = mild, 3 = moderate, 4 = severe, 5 = extreme); patient's global assessment of disease activity (1 = very good, 2 = good, 3 = fair, 4 = poor, 5 = very poor); physician's global assessment of disease activity (1 = very good, 2 = good, 3 = fair, 4 = poor, 5 = very poor).

  5. Assess rescue painkillers medication [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    Rescue medication use will be recorded throughout the study duration by a diary file.

  6. Structural assessment [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (MRI) density measurements with T2 mapping protocol used as an indication of disc fluid and glycosaminoglycans (GAG) content. In addition MRI spectroscopy will provide an assessment of the chemical changes associated with disc degeneration. The "quality" of the patient's lumbar disc will be monitored non invasively using T2 weighted MRI sagittal images and T1spin/echo MRI at the same time points. Lumbar disc grading will be performed in the sagittal T2 weighted images by two experienced physicians independently, who will review each intervertebral disc (from L1-2 to L5-S1) by the modified Pfirrmann criteria.

  7. Evaluation of cost [ Time Frame: 12 months ]

    Comparison of medical and non-medical costs between the two groups of patients. Resource used in each arm will be collected in physical units in the eCRF at the clinical centre as follows:

    • Acute care medical hospitalisations related to IDD
    • Acute care surgical hospitalisations related to IDD
    • Rehabilitation hospitalisations related to IDD
    • Analgesics
    • Work disruption

  8. Incidence of Adverse Events (AE) [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    Report of Adverse Events (AE). If the study patients do not spontaneously report any AE occurrence since their last visit, they will be interviewed by the investigator filling a study-specific AE checklist for recording of symptoms and complaints.

  9. Assessment of vital signs [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    During each visit to the study centre, patients will undergo a physical examination with recording of vital signs (temperature, blood pressure, heart rate, height and weight).

  10. Evaluation of blood and urine analysis [ Time Frame: Baseline, 1, 3, 6 and 12 months ]
    During each visit to the study centre, patients will undergo blood sampling for assessment of routine lab tests (Haematology and Biochemistry) and urine analysis (dipstick).

  11. Analysis of chemical biomarkers for tissue degeneration [ Time Frame: Baseline, 3, 6 and 12 months ]
    Assessment of chemical biomarkers for tissue degeneration through MRI spectroscopy. MRI spectroscopy will be used to provide an assessment of the chemical changes associated with disc degeneration (Zuo et al. 2009).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Workers (it means subject has worked at least 2 months, even if not continuously, in the last 6 months)
  • Age between 18 and 65 years.
  • Signed informed consent.
  • Symptomatic chronic LBP due to moderate/severe IDD [modified Pfirrmann score 3-5 (Pfirrmann et al., 2001), Griffith score 4-8 (Griffith et al., 2007)] at max. 4 levels of the lumbar spine unresponsive to conservative treatment, physical and medical for at least 6 months. Physical treatment includes physiotherapy. Medical treatments includes AINS, paracetamol, opioids and myorelaxant.
  • Annulus fibrosus intact, demonstrated by MRI.
  • Pain baseline > 40 mm on VAS (0- 100).
  • NSAID washout of at least 2 days before screening.
  • Painkillers washout of at least 24 hours before screening.
  • For females of childbearing potential, a negative pregnancy test must be documented at Screening.
  • Men and women should use effective contraception during treatment and for at least 12 months after BM-MSC discontinuation. The complete list of contraceptive methods is described in the patient information sheet and in the paragraph 6.5. As a precautionary measure, breast-feeding should be discontinued during treatment with BM-MSC and should not be restarted after discontinuation of BM-MSC.

Exclusion Criteria:

  • Non-workers (it means that the person has worked less than 2 months, although not continuously, in the last 6 months)
  • Congenital or acquired diseases leading to spine deformations that may upset cell application (scoliosis, isthmus lesion, sacralization and hemisacralization, degenerative spondilolisthesis).
  • Spinal segmental instability assessed by dynamic X-Ray.
  • Symptomatic facet joints syndrome on MRI (facet joints hyperintensity and hypertrophy evaluated at coronal T2 weighted MRI).
  • Prior to the screening visit, has received:

    • Oral corticosteroid therapy within the previous 3 months, OR
    • Intramuscular, intravenous or epidural corticosteroid therapy within the previous 3 months
  • Presence of a 5th level with symptomatic IDD (modified Pfirrmann score 3-5, Griffith score 4-8) in the lumbar spine.
  • Spinal canal stenosis (Schizas score > B).
  • History of spinal infection.
  • Lumbar disc herniation and sciatica.
  • Endplate abnormality such as Schmorl's Nodes.
  • Previous discal puncture or previous spine surgery.
  • IDD with Modic III changes on MRI images.
  • Patients not eligible to the intravertebral disc surgery.
  • Patients who have the risk to undergo a surgery in the next 6 months.
  • Patients with local infusion device/devices for corticosteroids.
  • Obesity with body mass index (BMI in Kg/size in m2) greater than 35 (obesity grade II).
  • Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study.
  • Abnormal blood tests: hepatic (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] >1.5 × upper limit of normal [ULN]), renal, pancreatic or biliary disease, blood coagulation disorders, anemia or platelet count of <100 × 109/L.
  • Pregnant or lactating women, or premenopausal women not using an acceptable form of birth control, are ineligible for inclusion. Contraception will be maintained during treatment and until the end of relevant systemic exposure. Additional pregnancy testing will be performed at the end of relevant systemic exposure. The patients will be required to use contraception from initial treatment administration until 24 months after the last dose of study drug.
  • In each case of delayed menstrual period (over 1 month between menstruations), confirmation of absence of pregnancy is strongly recommended. The complete list of contraceptive methods is described in the patient information sheet.
  • Positive serology for following infection: Syphilis, HIV, Hepatitis B, or C.
  • Contraindication to MRI assessed by the investigator.
  • Intolerance or allergy to local anaesthesia.
  • Any history of Cancer or immunodeficiency disease.
  • Previous transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04759105


Contacts
Layout table for location contacts
Contact: Gianluca Vadalà, MD, PhD +39 06 225419187 g.vadala@gmail.com

Locations
Layout table for location information
Italy
Campus Bio-Medico University of Rome Recruiting
Roma, Italy, 00128
Contact: Gianluca Vadalà, MD, PhD    +39 06 225419187    g.vadala@gmail.com   
Sponsors and Collaborators
Campus Bio-Medico University
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Center for Outcomes Research and Clinical Epidemiology, Italy
Investigators
Layout table for investigator information
Principal Investigator: Gianluca Vadalà, MD, PhD Campus Bio-Medico University of Rome
Layout table for additonal information
Responsible Party: Gianluca Vadalà, Professor, MD, PhD, Campus Bio-Medico University
ClinicalTrials.gov Identifier: NCT04759105    
Other Study ID Numbers: ACTIVE trial_(BRIC2018-ID03)
2019-004476-19 ( EudraCT Number )
First Posted: February 18, 2021    Key Record Dates
Last Update Posted: February 18, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Gianluca Vadalà, Campus Bio-Medico University:
Low back pain
Spine
Intervertebral disc degeneration
Mesenchymal stem cells
Bone marrow
Additional relevant MeSH terms:
Layout table for MeSH terms
Intervertebral Disc Degeneration
Back Pain
Low Back Pain
Pain
Neurologic Manifestations
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases